Manufacturers only have one chance to gain provider acceptance for a new specialty drug. With so many challenges that may decrease the real-world performance of the medication, CareMetx Chief Patient Experience Officer Jessica Lens explains that patient engagement is a critical factor ensuring the success of new drug launches.
Access and affordability are typically more central to the design of patient services programs. Prioritizing patient adherence to therapy regimens, particularly for complex medications, can mitigate the risks of patients stopping their treatment. “While the importance of integrating adherence into patient services programs is widely acknowledged in theory,” Lens explains, “the practical application of this understanding is often lacking, resulting in programs that do not fully facilitate optimal medication use.”
However, adherence contributes to better patient experiences, better health outcomes, and ultimately brand success. "How Patient Engagement Can Reduce Brand Launch Risk" explores this topic in more depth while also discussing strategies to help manufacturers evaluate hub vendors on adherence.